RxDoctor Payments Data

Syed Jamal, MD

Internal Medicine · Jacksboro, TXNPI 1437157419

Payments from drug & device makers

$13,302in general payments, 2019–2025

Across 18 payments — averaging $739.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Merz North America, Inc.$99
  • Teva Pharmaceuticals USA, Inc.$24
  • Neurocrine Biosciences, Inc.$22
  • Otsuka America Pharmaceutical, Inc.$14

What the payments were for

  • Speaking & faculty fees$12,82196%
  • Food & beverage$4814%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,302 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$760,401
Medicare patients
1,067
Services billed
21,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate82$362,171
EliquisApixaban996$304,152
BiktarvyBictegrav/Emtricit/Tenofov Ala31$133,050
GemtesaVibegron449$111,306
XareltoRivaroxaban175$50,038
JanuviaSitagliptin Phosphate152$48,410
JardianceEmpagliflozin142$47,492
SantylCollagenase Clostridium Hist.16$47,285
Abilify MaintenaAripiprazole12$38,154
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$37,055
VelphoroSucroferric Oxyhydroxide19$36,579
OtezlaApremilast13$29,914
Divalproex Sodium621$25,083
XifaxanRifaximin16$24,679
Potassium Chloride1,045$23,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$362,17182 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$14$38,15412 claims
AbbVieNamzaric, Linzess$13,143$19,17747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Jacksboro

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →